4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine Liquid. A 10 mM (1 mg/236 µl) solution in DMSO. PROTECT FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A cell-permeable 2-benzylsulfanyl imidazole that combines the structural features of cytokine release inhibitors SKF-86002 (Cat. No. 567305) and p38 MAP kinase inhibitor SB 203580 (Cat. No. 559389). Acts as an effective inhibitor of TNF-a and IL-1b release from mononuclear cells in human whole blood and peripheral blood mononuclear cells (IC50 = 20.3 µM and 3.65 µM for TNF-a; 2.78 µM and 0.88 µM for IL-1b, respectively). Occupies the ATP binding site of p38 MAP kinase and inhibits its activity (IC50 = 4.0 µM). Purity: >95% by HPLC. Ref.: Laufer, S.A., and Wagner, G.K. 2002. J. Med. Chem. 45, 2733.
R: 36/38; S: 26
Sold under license of U.S. Patent 6,432,988. | 
